GlassScriptPhysician profile
Shamili Allam
NPI 1912448226
$4,718.46
in general payments reported to CMS, 2019-2025
20 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $173 · 2021: $1,540 · 2022: $1,521 · 2023: $1,183 · 2024: $123 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,484.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $975.35 | 2021-2023 | Avvigo Guidance System, Ilab Ultrasound Imaging System, Rotapro |
| Biotronik INC. | $894.12 | 2021-2024 | Edora 8 Dr-T, Acticor 7 Vr-T Dx, Biomonitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $667.64 | 2021-2023 | Lifevest |
| Shockwave Medical, INC | $581.24 | 2021-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abbott Laboratories | $405.36 | 2021-2023 | Dragonfly Opstar |
| Abiomed | $394.50 | 2020-2023 | Impella |
| Janssen Pharmaceuticals, INC | $145.31 | 2020-2021 | |
| Amgen INC. | $141.46 | 2022-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $121.74 | 2021-2025 | Camzyos, Eliquis |
| Celgene Corporation | $101.45 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.34 | 2024-2025 | Jardiance |
| Pfizer INC. | $41.42 | 2022-2023 | |
| Philips North America LLC | $31.49 | 2024 | (Ck7) Extended Holter |
| Heartflow, INC. | $31.03 | 2022 | |
| Chiesi USA, INC. | $28.60 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $27.64 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.75 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $19.59 | 2025 | Wainua |
| Kestra Medical Technology Services, INC. | $16.00 | 2025 | Assure Wcd |
| Cathworks, INC. | $14.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shamili Allam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.